MedTrace Logo

Use of Ibandronate in Diabetic Patients

NCT05266261 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2022-03-04

No results posted yet for this study

Summary

The purpose of this study is to examine whether monthly oral administration of ibandronate to postmenopausal osteoporosis patients with type 2 diabetes differs in safety and efficacy compared to patients without diabetes.

Conditions

Interventions

DRUG

Ibandronate Oral Tablet

150 mg of ibandronate + 24,000 IU of cholecalciferol

Sponsors & Collaborators

  • Samsung Medical Center

    collaborator OTHER

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Yeouido St. Mary's Hospital

    lead OTHER

Principal Investigators

  • Ki-Hyun Baek, M.D., Ph.D. · Yeouido St. Mary's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2021-08-30
Completion
2022-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05266261 on ClinicalTrials.gov